Sitagliptin
- Generic Name
- Sitagliptin
- Brand Names
- Janumet, Januvia, Ristaben, Steglujan, Tesavel, Velmetia, Xelevia, Sitagliptin SUN, Sitagliptin Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H15F6N5O
- CAS Number
- 486460-32-6
- Unique Ingredient Identifier
- QFP0P1DV7Z
- Background
Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar. Sitagliptin was granted FDA approval on Oct...
- Indication
Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not used to treat type 1 diabetes or patients with a history of pancreatitis.
It is also used in combination with metformin or ertugliflozin.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)
- Conditions
- Interventions
- First Posted Date
- 2009-04-21
- Last Posted Date
- 2017-05-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 313
- Registration Number
- NCT00885352
Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension
- Conditions
- Interventions
- First Posted Date
- 2009-04-15
- Last Posted Date
- 2014-06-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 660
- Registration Number
- NCT00881530
- Locations
- 🇺🇸
1245.24.101006 Boehringer Ingelheim Investigational Site, Wadsworth, Ohio, United States
🇺🇸1245.24.101024 Boehringer Ingelheim Investigational Site, St. Cloud, Florida, United States
🇺🇸1245.24.101015 Boehringer Ingelheim Investigational Site, Dallas, Texas, United States
Sitagliptin Umbilical Cord Blood Transplant Study
- Conditions
- Interventions
- First Posted Date
- 2009-03-17
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- Indiana University School of Medicine
- Target Recruit Count
- 29
- Registration Number
- NCT00862719
- Locations
- 🇺🇸
IU Simon Cancer Center, Indianapolis, Indiana, United States
Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2009-03-12
- Last Posted Date
- 2020-12-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1988
- Registration Number
- NCT00860288
- Locations
- 🇰🇷
Ajou university hospital, Suwon, Korea, Republic of
🇱🇻Daugavpils Regional Hospital, Daugavpils, Latvia
🇱🇻Talsi Clinical Hospital, Talsi, Latvia
Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2009-03-04
- Last Posted Date
- 2013-10-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 182
- Registration Number
- NCT00855166
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Effect of Sitagliptin on Graft Function Following Islet Transplantation
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2017-10-30
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 12
- Registration Number
- NCT00853944
- Locations
- 🇨🇦
Vancouver General Hospital, Vancouver, British Columbia, Canada
Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial
- Conditions
- Interventions
- First Posted Date
- 2009-02-26
- Last Posted Date
- 2012-10-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 112
- Registration Number
- NCT00851903
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2009-02-12
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 18
- Registration Number
- NCT00842556
- Locations
- 🇺🇸
Ppd Development, Austin, Texas, United States
Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes
- First Posted Date
- 2009-02-09
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1049
- Registration Number
- NCT00838903
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2009-02-05
- Last Posted Date
- 2013-01-03
- Target Recruit Count
- 7
- Registration Number
- NCT00837759
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.